Form 4 Filing for Anika Therapeutics, Inc. - Officer/Director Transaction

This filing details a transaction by John B. Henneman III, a director at Anika Therapeutics, Inc. On June 18, 2026, 10,402 shares of Common Stock were acquired. The transaction code is "A," indicating an acquisition. The acquisition price was $0.00 per share, suggesting these shares were likely granted as restricted stock units (RSUs) which vest in full on the earlier of the 2027 annual meeting or June 18, 2027, as indicated by footnote F1. Following this transaction, Mr. Henneman holds 65,273 shares of Common Stock, with his ownership nature designated as direct ("D").